{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:10:49Z","timestamp":1785352249617,"version":"3.55.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01MH123396"],"award-info":[{"award-number":["R01MH123396"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24AI167805"],"award-info":[{"award-number":["K24AI167805"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30MH062246"],"award-info":[{"award-number":["P30MH062246"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30AI027763"],"award-info":[{"award-number":["P30AI027763"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23AG084415"],"award-info":[{"award-number":["K23AG084415"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30AI050409"],"award-info":[{"award-number":["P30AI050409"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Long-acting injectable (LAI) cabotegravir\/rilpivirine (CAB\/RPV) offers a novel drug delivery option for persons with human immunodeficiency virus (PWH) but requires administration every 4 or 8 weeks by a medical professional.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>To facilitate LAI antiretroviral therapy (ART) scale-up, we evaluated patient interest in alternative administration approaches via a mixed-methods, serial cross-sectional study across 3 US HIV clinics. We surveyed PWH (December 2021 to May 2022) on appeal of self- or partner\/friend\/family-administered LAI-CAB\/RPV; multivariable ordinal logistic regression explored associated characteristics. To contextualize survey results, we thematically analyzed semi-structured interview data collected from PWH (August 2020 to July 2021) on attitudes toward out-of-clinic LAI-ART administration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 370 surveyed PWH (median age, 46 years; 26% cisgender female, 59% Black, 56% sexual minority, 34% housing instability), self-administering LAI-CAB\/RPV appealed to 67%. PWH who were White (adjusted odds ratio [aOR], 3.30 [95% confidence interval {CI}, 1.42\u20137.64]), stably housed (aOR, 2.16 [95% CI, 1.30\u20133.59]), or gay\/bisexual (aOR, 1.81 [1.14\u20132.89]) were more likely to endorse self-administration. Fewer PWH (60%) reported partner\/friend\/family administration as appealing; adjusted models revealed similar sociodemographic preferences for this outcome. In 72 interviews, PWH noted that acceptability of out-of-clinic LAI-ART administration was qualified by convenience, prior injection experience, and potential fear of self-inflicted pain, dependence on others, and\/or HIV disclosure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In a multisite sample of PWH, self- and, to a lesser extent, partner\/friend\/family-administration of LAI-CAB\/RPV appealed to most; however, was less appealing among populations more impacted by health disparities. Innovative LAI-ART delivery options could free up in-clinic resources to focus scale-up among marginalized populations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofae265","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T16:56:39Z","timestamp":1715619399000},"source":"Crossref","is-referenced-by-count":12,"title":["Patient Attitudes Toward Self- or Partner-, Friend-, or Family-Administered Long-acting Injectable Antiretroviral Therapy: A Mixed-Methods Study Across 3 Urban Human Immunodeficiency Virus Clinics"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0170-5454","authenticated-orcid":false,"given":"Lauren F","family":"Collins","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia , USA"},{"name":"Ponce de Leon Center, Grady Health System , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A","family":"Koester","sequence":"additional","affiliation":[{"name":"Division of Prevention Science, Department of Medicine, Center for AIDS Prevention Studies, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9651-254X","authenticated-orcid":false,"given":"Moira C","family":"McNulty","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Infectious Diseases and Global Health, University of Chicago , Chicago, Illinois , USA"},{"name":"Chicago Center for HIV Elimination, University of Chicago , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth T","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco , San Francisco, California , USA"},{"name":"Women\u2019s Global Health Imperative, RTI International , Berkeley, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallory O","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Prevention Science, Department of Medicine, Center for AIDS Prevention Studies, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten B","family":"Neilands","sequence":"additional","affiliation":[{"name":"Division of Prevention Science, Department of Medicine, Center for AIDS Prevention Studies, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha E","family":"Dilworth","sequence":"additional","affiliation":[{"name":"Division of Prevention Science, Department of Medicine, Center for AIDS Prevention Studies, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1975-3080","authenticated-orcid":false,"given":"John A","family":"Sauceda","sequence":"additional","affiliation":[{"name":"Division of Prevention Science, Department of Medicine, Center for AIDS Prevention Studies, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaylin","family":"Dance","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia , USA"},{"name":"Ponce de Leon Center, Grady Health System , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Erguera","sequence":"additional","affiliation":[{"name":"Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California, San Francisco , San Francisco, California , USA"},{"name":"Department of Public Health, Zuckerberg San Francisco General Hospital , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manami","family":"Diaz Tsuzuki","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Jos\u00e9 I","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Department of Family Health Care Nursing, School of Nursing, University of California, San Francisco , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina A","family":"Christopoulos","sequence":"additional","affiliation":[{"name":"Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California, San Francisco , San Francisco, California , USA"},{"name":"Department of Public Health, Zuckerberg San Francisco General Hospital , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A","family":"Colasanti","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine , Atlanta, Georgia , USA"},{"name":"Ponce de Leon Center, Grady Health System , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"2024062715571518600_ofae265-B1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/aid.2020.0126","article-title":"The LAIs are coming! implementation science considerations for long-acting injectable antiretroviral therapy in the United States: a scoping review","volume":"37","author":"Kanazawa","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024062715571518600_ofae265-B2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2019.1343","article-title":"Ending the HIV epidemic: a plan for the United States","volume":"321","author":"Fauci","year":"2019","journal-title":"JAMA"},{"key":"2024062715571518600_ofae265-B3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40545-023-00559-8","article-title":"Access to a novel first-line single-tablet HIV antiretroviral regimen in Affordable Care Act marketplace plans, 2018\u20132020","volume":"16","author":"Khazanchi","year":"2023","journal-title":"J Pharm Policy Pract"},{"key":"2024062715571518600_ofae265-B4","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/aje\/kwac006","article-title":"One pill, once a day: simplified treatment regimens and retention in HIV care","volume":"191","author":"Bor","year":"2022","journal-title":"Am J Epidemiol"},{"key":"2024062715571518600_ofae265-B5","author":"Centers for Disease Control and Prevention"},{"key":"2024062715571518600_ofae265-B6","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"2024062715571518600_ofae265-B7","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"2024062715571518600_ofae265-B8","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"key":"2024062715571518600_ofae265-B9"},{"key":"2024062715571518600_ofae265-B10","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10461-020-03055-1","article-title":"Physical, emotional, and psychosocial challenges associated with daily dosing of HIV medications and their impact on indicators of quality of life: findings from the Positive Perspectives Study","volume":"25","author":"de Los Rios","year":"2021","journal-title":"AIDS Behav"},{"key":"2024062715571518600_ofae265-B11","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1016\/S2352-3018(22)00031-5","article-title":"Equity in access to long-acting injectables in the USA","volume":"9","author":"Hojilla","year":"2022","journal-title":"Lancet HIV"},{"key":"2024062715571518600_ofae265-B12","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1093\/cid\/ciac631","article-title":"First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable human immunodeficiency virus (HIV) viremia in an urban HIV clinic","volume":"76","author":"Christopoulos","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024062715571518600_ofae265-B13","doi-asserted-by":"crossref","first-page":"ofac455","DOI":"10.1093\/ofid\/ofac455","article-title":"Early experience implementing long-acting injectable cabotegravir\/rilpivirine for human immunodeficiency virus-1 treatment at a Ryan White\u2013funded clinic in the US South","volume":"9","author":"Collins","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024062715571518600_ofae265-B14","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/M23-0788","article-title":"Demonstration project of long-acting antiretroviral therapy in a diverse population of people with HIV","volume":"176","author":"Gandhi","year":"2023","journal-title":"Ann Intern Med"},{"issue":"Suppl 4","key":"2024062715571518600_ofae265-B15","doi-asserted-by":"crossref","first-page":"S541","DOI":"10.1093\/cid\/ciac716","article-title":"Barriers to uptake of long-acting antiretroviral products for treatment and prevention of human immunodeficiency virus (HIV) in high-income countries","volume":"75","author":"Cooper","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"2024062715571518600_ofae265-B16","doi-asserted-by":"crossref","first-page":"e26099","DOI":"10.1002\/jia2.26099","article-title":"U.S. patient preferences for long-acting HIV treatment: a discrete choice experiment","volume":"26","author":"Graham","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"2024062715571518600_ofae265-B17","volume-title":"Conference on Retroviruses and Opportunistic Infections (CROI)","author":"Gutierrez","year":"2023"},{"issue":"Suppl 3","key":"2024062715571518600_ofae265-B18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/10810730.2012.712615","article-title":"Measurement variation across health literacy assessments: implications for assessment selection in research and practice","volume":"17","author":"Haun","year":"2012","journal-title":"J Health Commun"},{"key":"2024062715571518600_ofae265-B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-024-04315-0","article-title":"Acceptability of long-acting injectable antiretroviral therapy among people with HIV receiving care at three Ryan White funded clinics in the United States [manuscript published online ahead of print 10 April 2024]","author":"Erguera","year":"2024","journal-title":"AIDS Behav"},{"key":"2024062715571518600_ofae265-B20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/QAD.0000000000003446","article-title":"Single-center experience evaluating and initiating people with HIV on long-acting cabotegravir\/rilpivirine","volume":"37","author":"Hill","year":"2023","journal-title":"AIDS"},{"key":"2024062715571518600_ofae265-B21","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1097\/QAD.0000000000003590","article-title":"HIV virologic response and baseline genotypic resistance in a long-acting cabotegravir\/rilpivirine initiation program","volume":"37","author":"Masich","year":"2023","journal-title":"AIDS"},{"key":"2024062715571518600_ofae265-B22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/cid\/ciad511","article-title":"Long-acting injectable cabotegravir\/rilpivirine effective in a small patient cohort with virologic failure on oral antiretroviral therapy","volume":"78","author":"Brock","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"2024062715571518600_ofae265-B23","doi-asserted-by":"crossref","first-page":"e26095","DOI":"10.1002\/jia2.26095","article-title":"The importance of the \u201chow\u201d: the case for differentiated service delivery of long-acting and extended delivery regimens for HIV prevention and treatment","volume":"26","author":"Grimsrud","year":"2023","journal-title":"J Int AIDS Soc"},{"key":"2024062715571518600_ofae265-B24","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/QAD.0000000000002746","article-title":"The COVID-19 pandemic as a catalyst for differentiated care models to end the HIV epidemic in the United States: applying lessons from high-burden settings","volume":"35","author":"Collins","year":"2021","journal-title":"AIDS"},{"key":"2024062715571518600_ofae265-B25","author":"Meissner"},{"key":"2024062715571518600_ofae265-B26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/QAI.0000000000003396","article-title":"Feasibility of implementing a low-barrier long-acting injectable antiretroviral program for HIV treatment and prevention for people experiencing homelessness","volume":"96","author":"Mehtani","year":"2024","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024062715571518600_ofae265-B27","author":"Felizarta"},{"key":"2024062715571518600_ofae265-B28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12954-023-00730-z","article-title":"Perspectives on long-acting injectable HIV antiretroviral therapy at an alternative care site: a qualitative study of people with HIV experiencing substance use and\/or housing instability","volume":"20","author":"Fletcher","year":"2023","journal-title":"Harm Reduct J"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae265\/57572022\/ofae265.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/6\/ofae265\/58215875\/ofae265.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/6\/ofae265\/58215875\/ofae265.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T19:05:07Z","timestamp":1719515107000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae265\/7671036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae265","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,5,13]]},"article-number":"ofae265"}}